Cargando…

Brain metastases in cancer patients attending a Gamma Knife Center: A study from a single institute in Iran

BACKGROUND: This study was aimed to explore data on brain metastases in cancer patients attending the Iranian Gamma Knife Center. METERIALS AND METHODS: This was a retrospective study. In all 5216 case records of patients who referred to the Iranian Gamma Knife Center for treatment of brain tumors d...

Descripción completa

Detalles Bibliográficos
Autores principales: Azimi, Parisa, Shahzadi, Sohrab, Bitaraf, Mohammad Ali, Azar, Maziar, Alikhani, Mazdak, Zali, Alireza, Sadeghi, Sohrab, Montazeri, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532943/
https://www.ncbi.nlm.nih.gov/pubmed/28761536
http://dx.doi.org/10.4103/1793-5482.145564
_version_ 1783253547141300224
author Azimi, Parisa
Shahzadi, Sohrab
Bitaraf, Mohammad Ali
Azar, Maziar
Alikhani, Mazdak
Zali, Alireza
Sadeghi, Sohrab
Montazeri, Ali
author_facet Azimi, Parisa
Shahzadi, Sohrab
Bitaraf, Mohammad Ali
Azar, Maziar
Alikhani, Mazdak
Zali, Alireza
Sadeghi, Sohrab
Montazeri, Ali
author_sort Azimi, Parisa
collection PubMed
description BACKGROUND: This study was aimed to explore data on brain metastases in cancer patients attending the Iranian Gamma Knife Center. METERIALS AND METHODS: This was a retrospective study. In all 5216 case records of patients who referred to the Iranian Gamma Knife Center for treatment of brain tumors during year 2003-2011 were reviewed. Data were explored to identify patients who developed brain metastases due to cancer and assessed the information as applied to cancer patients including survival analysis. RESULTS: Two hundred and twenty patients were identified as having brain metastases due to cancer. The mean age of patients was 54.0 (standard deviation [SD] =12.7) years. Patients were followed for an average of 7 months after treatment with gamma-knife. The median survival time for different the Graded Prognostic Assessment (GPA) was: GPA: 0-1, 4.0 ± 0.4 months; GPA: 1.5-2.5, 6.0 ± 0.7 months; GPA: 3, 9.0 ± 0.9 months; and GPA: 3.5-4.0, 12.0 ± 1.8 months and the overall median survival was 7.0 (SD = 0.6) months. CONCLUSION: The findings suggest that many cancer patients in Iran might develop brain metastasis. Although, this is not a very high incidence compared with the existing statistics from other countries, there is an urgent need to explore the issue further.
format Online
Article
Text
id pubmed-5532943
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-55329432017-07-31 Brain metastases in cancer patients attending a Gamma Knife Center: A study from a single institute in Iran Azimi, Parisa Shahzadi, Sohrab Bitaraf, Mohammad Ali Azar, Maziar Alikhani, Mazdak Zali, Alireza Sadeghi, Sohrab Montazeri, Ali Asian J Neurosurg Original Article BACKGROUND: This study was aimed to explore data on brain metastases in cancer patients attending the Iranian Gamma Knife Center. METERIALS AND METHODS: This was a retrospective study. In all 5216 case records of patients who referred to the Iranian Gamma Knife Center for treatment of brain tumors during year 2003-2011 were reviewed. Data were explored to identify patients who developed brain metastases due to cancer and assessed the information as applied to cancer patients including survival analysis. RESULTS: Two hundred and twenty patients were identified as having brain metastases due to cancer. The mean age of patients was 54.0 (standard deviation [SD] =12.7) years. Patients were followed for an average of 7 months after treatment with gamma-knife. The median survival time for different the Graded Prognostic Assessment (GPA) was: GPA: 0-1, 4.0 ± 0.4 months; GPA: 1.5-2.5, 6.0 ± 0.7 months; GPA: 3, 9.0 ± 0.9 months; and GPA: 3.5-4.0, 12.0 ± 1.8 months and the overall median survival was 7.0 (SD = 0.6) months. CONCLUSION: The findings suggest that many cancer patients in Iran might develop brain metastasis. Although, this is not a very high incidence compared with the existing statistics from other countries, there is an urgent need to explore the issue further. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5532943/ /pubmed/28761536 http://dx.doi.org/10.4103/1793-5482.145564 Text en Copyright: © 2014 Asian Journal of Neurosurgery http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Azimi, Parisa
Shahzadi, Sohrab
Bitaraf, Mohammad Ali
Azar, Maziar
Alikhani, Mazdak
Zali, Alireza
Sadeghi, Sohrab
Montazeri, Ali
Brain metastases in cancer patients attending a Gamma Knife Center: A study from a single institute in Iran
title Brain metastases in cancer patients attending a Gamma Knife Center: A study from a single institute in Iran
title_full Brain metastases in cancer patients attending a Gamma Knife Center: A study from a single institute in Iran
title_fullStr Brain metastases in cancer patients attending a Gamma Knife Center: A study from a single institute in Iran
title_full_unstemmed Brain metastases in cancer patients attending a Gamma Knife Center: A study from a single institute in Iran
title_short Brain metastases in cancer patients attending a Gamma Knife Center: A study from a single institute in Iran
title_sort brain metastases in cancer patients attending a gamma knife center: a study from a single institute in iran
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532943/
https://www.ncbi.nlm.nih.gov/pubmed/28761536
http://dx.doi.org/10.4103/1793-5482.145564
work_keys_str_mv AT azimiparisa brainmetastasesincancerpatientsattendingagammaknifecenterastudyfromasingleinstituteiniran
AT shahzadisohrab brainmetastasesincancerpatientsattendingagammaknifecenterastudyfromasingleinstituteiniran
AT bitarafmohammadali brainmetastasesincancerpatientsattendingagammaknifecenterastudyfromasingleinstituteiniran
AT azarmaziar brainmetastasesincancerpatientsattendingagammaknifecenterastudyfromasingleinstituteiniran
AT alikhanimazdak brainmetastasesincancerpatientsattendingagammaknifecenterastudyfromasingleinstituteiniran
AT zalialireza brainmetastasesincancerpatientsattendingagammaknifecenterastudyfromasingleinstituteiniran
AT sadeghisohrab brainmetastasesincancerpatientsattendingagammaknifecenterastudyfromasingleinstituteiniran
AT montazeriali brainmetastasesincancerpatientsattendingagammaknifecenterastudyfromasingleinstituteiniran